| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -4,323,177 | 346,850 |
| Amortization of debt discount | 234,369 | 200,888 |
| Amortization of capitalized software | 7,087,054 | 4,627,520 |
| Amortization of intangibles | 775,338 | 505,888 |
| Loss on debt extinguishment | -1,155,851 | - |
| Accretion of consideration payable | - | 0 |
| Depreciation of fixed assets | 609,569 | 346,822 |
| Noncash operating lease expense | 821,604 | 577,689 |
| Stock compensation expense | 7,841,178 | 4,643,142 |
| Accounts receivable | -1,609,763 | -887,684 |
| Product deposit | 329,755 | 210,237 |
| Inventory | 635,024 | 453,997 |
| Other current assets | 580,382 | -707,257 |
| Operating lease liabilities | -248,574 | -198,901 |
| Deferred revenue | -5,270,408 | -2,690,893 |
| Accounts payable | 3,545,251 | 8,283,386 |
| Accrued expenses | -731,959 | -5,865,264 |
| Net cash provided by operating activities | 11,560,698 | 11,707,834 |
| Cash paid for capitalized software costs | 8,446,187 | 5,648,965 |
| Purchase of equipment | 1,715,214 | 917,956 |
| Purchase of intangible assets | - | 0 |
| Net cash used in investing activities | -10,161,401 | -6,566,921 |
| Repayment of notes payable, net of prepayment penalty | - | 0 |
| Repayment of debt instruments | 18,719,721 | 2,052,288 |
| Sale of common stock under atm, net | 8,721,717 | - |
| Preferred stock dividends | 2,329,688 | 1,553,125 |
| Cash proceeds from exercise of warrants | 464,950 | - |
| Cash proceeds from exercise of options | 5,950 | 0 |
| Contingent consideration payments for resumebuild acquisition | - | 0 |
| Distributions to non-controlling interest | 761,658 | 312,119 |
| Net cash used in financing activities | -12,618,450 | -3,917,532 |
| Net (decrease) increase in cash | -11,219,153 | 1,223,381 |
| Cash and cash equivalents at beginning of period | 35,004,924 | - |
| Cash and cash equivalents at end of period | 23,785,771 | - |
LifeMD, Inc. (LFMD)
LifeMD, Inc. (LFMD)